

- **Name:** Emile Eugene Voest
- **Current Position & Affiliation:** Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht
- **Country:** The Netherlands

• **Educational Background:**

1971-1977	Gymnasium, Zeist
1978	Chemistry, Utrecht University, The Netherlands
1978-1985	Utrecht University School of Medicine; Utrecht, The Netherlands
1985 MD	Utrecht University School of Medicine; Utrecht, The Netherlands
1993 PhD	University of Utrecht, The Netherlands (cum laude) Dissertation: "Iron chelation, Oxygen radicals, and Anthracyclines in the Treatment of Cancer"

• **Professional Experience:**

1999-	Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht
2010-	Chair of the Scientific Advisory Board of InteRNA
2013-	Editorial board of Clinical Cancer Research
2014-	Senior Group Leader Netherlands Cancer Institute
2015-	Editorial board of JAMA Oncology
2015-	Member of supervisory board Hartwig Medical Foundation
2016-	Editorial board ESMO Open, Cancer Horizons
2016-	Executive Board of Cancer Core Europe
2019-	Senior Group Leader of the Oncode Institute
2019-	Advisor of Agalia Venture Capital
2019-	Managing director, Executive Board of Directors, Cancer Core Europe
2021-	Scientific Advisory Committee (SAC) for Omico (trading as the Australian Genomic Cancer Medicine Centre (AGCMC))
2021-	Clinical Advisory Board Cambridge Cancer Center, UK
2021-	Scientific Advisory Board Institute Gustave Roussy, Paris, France
2021-	Scientific Advisory Board GROW Oncology, Maastricht, Netherlands

• **Professional Organizations:**

- American Association for Cancer Research
- Dutch Association for Oncology
- Dutch Association for Medical Oncology
- European Society for Medical Oncology
- Dutch Association for Internal Medicine

• **Main Scientific Publications:**

2022

1. L.R. Hoes^{1,2}, J.M. van Berge Henegouwen^{2,3}, H. van der Wijngaart^{2,4}, L.J. Zeverijn^{1,2}, D.L. van der Velden¹, J. van de Haar^{1,2,5}, P. Roepman⁶, W.W.J. de Leng⁷, A.M.L. Jansen⁷, E. van Werkhoven⁸, V. van der Noort⁸, A.D.R. Huitema^{9,10,11}, E.H. Gort¹², J.W.B. de Groot¹³, E.D. Kerver¹⁴, D.J. de Groot¹⁵, F. Erdkamp¹⁶, L.V. Beerepoot¹⁷, M.P. Hendriks¹⁸, E.F. Smit¹⁹, W.T.A. van der Graaf²⁰, C.M.L. van Herpen²¹, M. Labots³, A. Hoeben²², H. Morreau²³, M.P. Lolkema^{24,26}, E. Cuppen^{2,6,25}, H. Gelderblom³, H.M.W. Verheul²¹, **E.E. Voest**^{1,2,26} Genomics – Guided Treatment of Patients With Rare Cancers in the Drug Rediscovery Protocol (DRUP). *Clin Cancer Res* 2022, in press

2021

1. Mulder J, Verjans R, Verbaanderd C, Pean E, Weemers J, Leufkens HGM, Pignatti F, de Boer A, **Voest EE**, Stoyanova-Beninska VV, Pasmooij AMG. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. *Front Med*. 2021 Dec 9; 8:790782.
2. L.J. Zeverijn^{*1,2}, S. Barjesteh van Waalwijk van Doorn-Khosrovani^{*3}, A. Pisters-van Roy³, L. Timmers⁴, T.H.L. Tran⁴, J.E. de Boer⁴, G.F. de Wit^{1,2}, B.S. Geurts^{1,2}, H. Gelderblom⁵, H.M.W. Verheul⁶, N. Blijlevens⁷, A.N.M. Wymenga⁸, F.A.L.M. Eskens⁹, E.F. Smit^{10,11}, H.J. Bloemendal⁶, **E.E. Voest**^{1,2} Harmonising patient-access programmes: the Dutch DRUG Access Platform. *Lancet Oncology* 2021, in press
3. Veninga V, **Voest E**. Tumor organoids: Opportunities and challenges to guide precision medicine. *Cancer Cell*, 2021; Sep 13;39(9):1190-1201
4. David Tamborero*, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Irene Braña, Luigi De Petris, Jeffrey Yachnin, Richard Baird, Christophe Massard, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Cancer Core Europe consortium, Judith Balmaña, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Fröhling, Elena Garralda, Claes Karlsson, Josep Tabernero, **Emile Voest**, Jordi Rodon, Janne Lehtiö.* Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network. *Nature Cancers* 2021, in press
5. Joris van de Haar^{1,2,3}, Louisa R. Hoes^{1,3}, Paul Roepman⁴, Martijn P. Lolkema⁵, Henk M.W. Verheul⁶, Hans Gelderblom⁷, Adrianus J. de Langen⁸, Egbert F. Smit⁸, Edwin Cuppen^{3,4,9}, Lodewyk F.A. Wessels, **Emile E. Voest**. Limited Evolution of the Actionable Metastatic Cancer Genome Under Therapeutic Pressure. *Nature Medicine* 2021, 27(9):1553-1563
6. L. Kester, D. Seinstra, A.G.J. van Rossum, Claire Vennin, M. Hoogstraat, D. van der Velden, M. Opdam, E. van Werkhoven, Kerstin Hahn, I. Nederlof, E. H. Lips, I.A.M. Mandjes, A.E. van Leeuwen – Stok, S. Canisius, H. van Tinteren, A.L.T. Imholz, J.E.A. Portielje, M.E.M.M. Bos, S. Bakker, E.J. Rutgers, H. M. Hurlings, J. Wesseling, **E. Voest**, L.F.A. Wessels, M. Kok, H.M. Oosterkamp, A. van Oudenaarden, S.C. Linn, J. van Rheeën Differential survival and therapy benefit of breast cancer patients are characterized by distinct epithelial and immune cell microenvironments. *Clin Cancer Res* 2021, in press
7. Jorn Mulder¹, Robin Verjans², Ciska Verbaanderd³, Elias Pean³, Just Weemers⁴, Hubertus G.M. Leufkens⁵, Francesco Pignatti³, Anthonius de Boer^{1,5}, **Emile E. Voest**^{6,7}, Violeta V. Stoyanova-Beninska¹, Anna M. G. Pasmooij¹. Extension of indication for oncology products: a joint effort of multiple stakeholders. *Frontiers in Medicine*, 2021, December 9
8. Claire E. McCarthy, Nastaran Zahir, Mariam Eljanne, Elad Sharon, **Emile E. Voest***, Karolina Palucka. * Developing and Validating Model Systems for Immuno-Oncology. *Cancer Cell* 2021, 39(8):1018-1022

9. H. van der Wijngaart^{1,2}, L. R. Hoes^{2,3}, J. M. van Berge Henegouwen^{2,4}, D. L. van der Velden⁵, L. J. Zeverijn^{2,3}, P. Roepman⁶, E. van Werkhoven⁷, W. W. J. de Leng⁸, A. M. L. Jansen⁸, N. Mehra⁹, D. G. J. Robbrecht¹⁰, M. Labots¹, D. J. A. de Groot¹¹, A. Hoeben¹², P. Hamberg¹³, H. Gelderblom⁴, **E. E. Voest**^{2,3}, H. M. W. Verheul⁹ The importance of bi-allelic inactivation of BRCA1/2 in patient selection for olaparib - a Drug Rediscovery Protocol (DRUP) cohort. Clin Cancer Res 2021, Sept 2
10. Gabriele Picco¹, Chiara Cattaneo^{2,5}, Esmée van Vliet¹, Giovanni Crisafulli³, Giuseppe Rospo³, Sarah Consonni¹, Sara Vieira¹, Iñigo Sánchez Ridríguez^{2,5}, Carlotta Cancelliere³, Ruby Banerjee¹, Luuk Schipper^{2,5}, Daniele Oddo³, Krijn Dijkstra^{2,5}, Jindrich Cinatl, Martin Michaelis, Fengtang Yang¹, Federica di Nicolantonio^{3,4}, Andrea Sartore Bianchi^{6,7}, Salvatore Siena^{6,7}, Sabrina Arena^{3,4}, **Emile Voest**^{2,5,#}, Alberto Bardelli^{3,4,#}, and Mathew J. Garnett^{1,#,*} Werner helicase Dependency is Retained in Mismatch Repair–Deficient Colorectal Cancers Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. Cancer Discovery, 2021 Aug;11(8):1923-1937
11. Susan Halabi¹, Pam Mangat², Elizabeth Garrett-Mayer², Hanneke van de Wijngaart³, Henk Verheul³, **Emile Voest**³, Lillian Siu⁴, Daniel J. Renouf⁵, Janet Dancey⁴, Richard L. Schilsky² Advancing Precision Oncology: TADRUCA, A Model for Global Collaboration. DIA Global Forum April 2021
12. Salo Noël Ooft, PhD,^{1,*} Fleur Weeber, MD, PhD,^{1,*} Luuk Schipper, MD,^{1,#} Krijn Kristian Dijkstra, MD, PhD,^{1,#} Chelsea Marie McLean, PhD,¹ Sovann Kaing BSc,¹ Joris van de Haar, MD, MSc,^{1,2} Warner Prevoo MD, PhD,³ Erik van Werkhoven PhD,⁴ Petur Snaebjornsson MD, PhD,⁵ Louisa Hoes, MD,¹ Myriam Chalabi, MD,^{1,6} Daphne van der Velden, MD, PhD,^{1,6,7} Monique van Leerdam, MD, PhD,⁶ Henk Boot MD, PhD,⁶ Cecile Grootsholten MD, PhD,⁶ Alwin Dagmar Redmar Huitema, MD, PhD,^{8,9} Haiko Johannes Bloemendal MD, PhD,¹⁰ Edwin Cuppen, PhD,^{11,12,13} and **Emile Voest** MD, PhD.^{1,6,13,14} Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open, 2021; Jun;6(3):100103
13. Krijn K Dijkstra, José G Van Den Berg, Fleur Weeber, Joris Van De Haar, Arno Velds, Sovann Kaing, Dennis D G C Peters, Ferry A L M Eskens, Derk-Jan A De Groot, Margot E T Tesselaar, **Emile Voest**. Patient-derived organoid models of human neuroendocrine carcinoma. Frontiers in Endocrinology, 2021,12:627819
14. Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin- Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, **Voest E**, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507-2543